Additional file 1: Figure S1



Additional file 1: Figure S1: Altered *Cx₃cl1* and *Cx₃cr1* mRNA expression in non-transgenic, *Cx₃cl1*$^{-/-}$, *Cx₃cl1*$^{105\Delta}$ mice as well as altered soluble CX₃CL1 protein levels in non-transgenic, *Cx₃cl1*$^{105\Delta}$/*Cx₃cl1*$^{+/+}$ and *Cx₃cl1*$^{105\Delta}$/*Cx₃cl1*$^{-/-}$ mice. (A) Quantitative real-time PCR (qRT-PCR) analysis shows significantly elevated *Cx₃cl1* mRNA levels in the brains of *Cx₃cl1*$^{105\Delta}$ mice compared to Non-Tg mice. *Cx₃cl1*$^{-/-}$ serves as negative control with no fractalkine mRNA expression. **(B)** ELISA analysis shows significantly elevated levels of soluble (sol.) fractalkine in the *Cx₃cl1*$^{105\Delta}$/*Cx₃cl1*$^{+/+}$ mice (which expresses CX₃CL1$^{105\Delta}$ along with endogenous CX₃CL1) compared to non-transgenic *Cx₃cl1*$^{105\Delta}$/*Cx₃cl1*$^{-/-}$ (which only expresses CX₃CL1$^{105\Delta}$) mice. **(C)** qRT-PCR analysis shows significantly elevated mRNA levels for *Cx₃cr1* in *Cx₃cl1*$^{105\Delta}$ mice (in *Cx₃cl1*$^{-/-}$ background) compared to Non-Tg, but not *Cx₃cl1*$^{-/-}$ mice. Data displayed as mean ± SEM; one-way ANOVA followed by Tukey post-hoc test: *$p < 0.05$, ***$p < 0.001$; n=3-6 mice per group).